Market Place
Sourcing Support
Starpharma names Justin Cahill as CFO and Company secretary
10 Mar 2023 //
BIOSPECTRUM ASIA
Starpharma presents compelling data in Prostate Cancer at ESMO
12 Sep 2022 //
PRNEWSWIRE
Merck bags chance to test ADCs based on Starpharma delivery tech
16 Aug 2022 //
FIERCEPHARMA
Starpharma signs new DEP research agreement with MSD
11 Aug 2022 //
PHARMABIZ
Starpharma signs new DEP agreement with MSD
10 Aug 2022 //
PR NEWSWIRE
Starpharma`s nasal spray effective against influenza A & B virus
23 May 2022 //
BIOSPECTRUMASIA
Anti-viral agent in Australian-developed nasal spray active against `Omicron`
04 Mar 2022 //
BIOSPECTRUMASIA
Starpharma reports positive Phase II interim data for prostate cancer
27 Nov 2021 //
CLINICALTRIALSARENA
Starpharma releases positive DEP® phase 2 interim results in prostate cancer
27 Nov 2021 //
PRNEWSWIRE
USPTO grants patent for DEP cabazitaxel in PII clinical-stage cancer treatments
15 Sep 2021 //
PRNEWSWIRE
Starpharma`s Nasal Spray Reduces SARS-CoV-2 by Over 99.9% in Animal Studies
23 Aug 2021 //
BIOSPACE
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model
23 Jul 2021 //
PRNEWSWIRE
WuXi STA Chooses Middletown Delaware for New Pharma Manufacturing Campus
29 Jun 2021 //
CONTRACTPHARMA
Starpharma to Webcast Live at Life Sciences Investor Forum June 24th
24 Jun 2021 //
GLOBENEWSWIRE
Australia`s Starpharma`s launches COVID-19 antiviral nasal spray VIRALEZE
01 Apr 2021 //
BIOSPECTRUMASIA
Starpharma to sell COVID-fighting nose spray in UK
25 Mar 2021 //
PHARMAFILE
Starpharma signs DEP® ADC Research Agreement with MSD
12 Feb 2021 //
PRNEWSWIRE
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
14 Sep 2020 //
PRESS RELEASE
Starpharma creates slow release soluble DEP remdesivir nanoparticle
01 Sep 2020 //
BUSINESSWIRE
Starpharma (ASX:SPL) creates long-acting version of COVID-19 drug remdesivir
01 Sep 2020 //
THEMARKETHERALD
SPL7013 nasal spray for COVID-19 – development update
25 Aug 2020 //
PRESS RELEASE
Starpharma: Commencement of Pha1 Trial for AZD0466 Utilising DEP® Technology
31 Dec 2019 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.